Project leads
Collaborators

A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT

Joseph H Antin

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

Follow

Joseph H Antin

Dana-Farber Cancer Institute

Boston, United States

Related projects

John Nicholas

BH3-only Protein Targeting by HHV-8

Non-Hodgkin lymphoma Hodgkin lymphoma

Leonid S Metelitsa

Integrated Instrument System for Single Cell Genomics

Non-Hodgkin lymphoma Hodgkin lymphoma

Pediatric oncology or childhood cancer

Peng Huang

Novel Strategies to Target Leukemia-Stromal Interactions

Lixin Wan

A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment

Mary V. Relling

Center for Precision Medicine in Leukemia (CPML)

Bruno Calabretta

Targeting the C/EBPalpha-Gfi-pathway in CML stem cells

Pathology Hematology and hematologic malignancies

M. James You

CHARACTERIZATION AND TARGETED THERAPY OF T-ALL DEFICIENT FOR PTEN AND INK4A/ARF

Wenwei Hu

The Role of LIF, a Novel Negative Regulator of p53, in Colorectal Cancer

Wei Gu

HAUSP inhibitors in p53-wild type and p53-mutant tumors

Non-Hodgkin lymphoma